

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. GP104-03.CN1	SERIAL NO. <del>To be assigned</del> 09/943,286
	APPLICANT Nunomura, K.	
	FILING DATE August 30, 2001	GROUP <del>To be Assigned</del> 1637

U.S. PATENT DOCUMENTS										
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS SUBCLASS
TS	4	6	8	3	1	9	5	07/28/87	Mullis et al.	435 6
	5	2	1	9	7	2	7	06/15/93	Wang et al.	435 6
	5	2	8	3	1	7	4	02/01/94	Arnold, Jr. et al.	435 6
	5	3	9	9	4	9	1	03/21/95	Kacian et al.	435 91.21
	5	7	0	5	3	6	5	01/06/98	Ryder et al.	435 91.1
TS	5	7	1	0	0	2	9	01/20/98	Ryder et al.	435 91.1

FOREIGN PATENT DOCUMENTS										
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	COUNTRY	CLASS SUBCLASS
TS	9	1	0	2	8	1	8	03/07/91	PCT	
	9	3	0	2	2	1	5	02/04/93	PCT	
	9	5	0	3	4	3	0	02/02/95	PCT	
	0	3	2	0	3	0	8	06/14/89	EP	
	0	4	9	7	2	7	2	08/05/92	EP	
	0	5	2	5	8	8	2	02/03/93	EP	
	0	5	8	7	2	6	6	03/16/94	EP	
	0	5	8	7	2	9	8	03/16/94	EP	
TS	0	6	2	3	6	8	2	11/09/94	EP	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)									
TS	A	Chelly et al., "Transcription of the dystrophin gene in human muscle and non-muscle tissues", <i>Nature</i> , 333:858-860 (June 1988)								
	B	Persing, "In Vitro Nucleic Acid Amplification Techniques", <i>Diagnostic Molecular Microbiology - Principles and Applications</i> , (Persing et al., eds.) Part 1, Chpt. 3, citing 2 sections: Quantitative PCR and Transcription-Based Amplification Systems: TAS and 3SR (incl. Figure 4.), pgs. 65-67 (1993)*								
	C	van Gemen et al., "A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes", <i>J. Virol. Meth.</i> , 49:157-168 (1994)*								
TS	D	Natarajan V. et al., "An Internally Controlled Virion PCR for the Measurement of HIV-1 RNA in Plasma", <i>PCR Methods and Applications</i> , Vol. 3, pp. 346-350 (June 1994)								

\*The year of publication is sufficiently earlier than the effective U.S. Filing date so that the particular month of publication is not in issue.

EXAMINER Teresa Strzelecka	DATE CONSIDERED 7/26/04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



Scan only !! Not in eDan.  
Please do not send to Applicant

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Applicant Number	09/943,286		
		Filing Date	August 30, 2001		
		First Named Inventor	NUNOMURA		
		Art Unit	1637		
		Examiner Name	Strzelecka		
Sheet	1	of	1	Attorney Docket Number	GP104-03.CN1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TS	✓	RATNER et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III", Nature, Jan 1985, 313:277-284	
TS	✓	VAN BEVERAN et al., "Appendix B: HTLV-3 genome", RNA Tumor Viruses, Molecular Biology of Tumor Viruses, Second Edition, 1985, 2:1106-1123	
TS	✓	HOSTOMSKY et al., "Reconstitution in vitro of RNase H Activity by Using Purified N-terminal and C-terminal Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", Proc. Natl. Acad. Sci. USA, Feb 1991, 88:1148-1152	

Examiner Signature	Teresa Strzelecka	Date Considered	12/16/03
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.